1) U.S. FDA Approves Bydureon(R) Pen (exenatide extended-release for injectable suspension) for Once-Weekly Treatment of Adults with Type 2 Diabetes - Wall Street Journal, March 3, 2014
AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has approved the Bydureon(R) Pen (exenatide extended-release for injectable suspension) 2 mg as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Bydureon should not be used for treatment of patients with type 1 diabetes or diabetic ketoacidosis. Link
2) FDA Approves Endo International’s testosterone drug - Reuters, March 6, 2014
Endo International Plc said the Food and Drug Administration approved its thrice-rejected testosterone replacement therapy, Aveed, to treat male hypogonadism. Link
3) Rare Disease Day on Beacon Hill - WWLP, February 28, 2014
It’s International Rare Disease Day. 22 News spoke with state lawmakers about their efforts to raise awareness. Thirty million people are affected by rare diseases in the country. A disease is considered rare if it affects fewer than 200,000 people, but everyone is impacted somehow. Link
4) Xenetic Biosciences Announces Opening of Corporate Headquarters and R&D Facility in Lexington, MA - Wall Street Journal, March 4, 2014
Xenetic Biosciences, Inc., a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, today announced the opening of its new corporate headquarters and research and development facility in Lexington, MA. Link
5) Alnylam closes $175M purchase of Merck subsidiary - Boston Business Journal, March 6, 2014
Alnylam Pharmaceuticals has closed its $175 million acquisition of Sirna Therapeutics Inc., a subsidiary of Merck & Co., it said Thursday. Link
MassBio is pleased to announce we will be doing another Forums series this year! In this Forum series, Around the World in 120 Days: Biotech on a Global Scale, industry leaders from around the world will share their advice on and experiences with the challenges and opportunities of global biotech business.
Part I: The World is Small: Understanding Biotech Business in the Global Framework
March 20, 8 – 10 am
Please join us for an insightful look at the current and expected global biopharma landscape, hear from seasoned veterans who have successfully launched and led global expansion initiatives and learn why you need to start thinking about your global strategy today.
- Pedro Arboleda, Director, Strategy, Monitor Deloitte
- Dane Bedward, Senior Life Science Executive, former Senior V.P. International Strategic Development and GM Eurasia, Genzyme
- Markus Warmuth, President and Chief Executive Officer, H3 Biomedicine
- Peter Abair, Director, Economic Development & Global Affairs, MassBio
- Angelos Dovletoglou, Executive Director, Preclinical Development Sciences, Epizyme
Part II: Europe 101: Opportunities for Collaboration & New Markets
April 10, 8 – 10 am
Please join us for the second part of the Around the World in 120 Days series as we introduce key concepts of doing business in Europe. Attendees will leave with a better understanding of opportunities and challenges in Europe such as how to access foreign markets, what opportunities and pitfalls exist, and how the cultural and business landscape changes the way you do business globally.
- Thor-Björn Conradson, MD, Consultant, Drug Development Counselling Group, KLIFO
- Peter Damsbo, MD, Consultant, Drug Development Counselling Group, KLIFO
- Dave Gilbert, Advisory Board, NDA Advisory Services, UK
- Scott Maguire, CEO, Xenetic Biosciences
- Mark Leuchtenberger, President and Chief Executive Officer, Acusphere, Inc.
Future Forums will include:
May 2014: Asia 101: Survey of the Life Sciences
June 2014: Latin America 101: Opportunities South of the Border
MassBio is excited to announce that this month we are launching two new types of networking events for our members!
Meet the Experts Networking Night
March 25th – 4:00pm
This event is designed for entry-level bench scientists who want to learn more about career paths beyond the bench, get face-time with experts in the field, and meet entry-level employees from other MassBio member companies!
We will have 5 tables each featuring a different potential career path: Drug Discovery, Intellectual Property, Business Development, Regulatory and Non-Profit. There will be structured networking through 15-minute rounds of Q&A with a specific life sciences leader in each particular area and the event will conclude with an hour of networking.
Celtics Networking Night
MassBio is proud to present Celtics Networking Night for our members! Take this opportunity to kick back with your fellow members outside of the MassBio headquarters. Price of ticket includes admission to an exclusive MassBio pre-game networking event at the Harp with food and drinks, and a balcony ticket to the game. Whether you are a die-hard Celtics fanatic or just a casual fan, Celtics games are always a good time, packed with lots of entertainment and fun all 4 quarters! So join MassBio in cheering Rajon Rando, Brandon Bass and rookie-star, Kelly Olynyk in leading the Celtics to a win.
Space is limited, so hurry to take part in this unique event!
Join MassBio April 3rd & 4th!
Royal Sonesta Hotel, 40 Edwin Land Blvd, Cambridge, MA
The MassBio Annual Meeting focuses on the most timely and critical challenges facing the Massachusetts biotechnology industry and it is only 1 month away! We will be back here soon to share more details, but today wanted to highlight our Conference-Wide Panels:
Conference-Wide Panels include:
Impact 2020 will assess the critical events, trends, policies and discoveries that will impact the life sciences sector through 2020 and make recommendations to ensure that the industry thrives in Massachusetts and continues to advance science in addressing the needs of our planet. The report will be officially released at our Annual Meeting and report leaders will discuss the findings and recommendations for the future during this panel session.
Value Cost Effectiveness: Implications of the Changing Landscape in Reimbursement and Regulations
This panel will continue the conversation on medical innovation and its relation to and impact on health care cost containment started at MassBio’s Policy Leadership Breakfast. Experts will discuss efforts to get a handle on the ever-rising cost of healthcare and new approaches to ensure patients receive quality care and breakthrough therapies.
Join us for these important conversations and for the chance to:
- Connect: Forge new scientific and business relationships
- Collaborate with industry scientists, CSOs and other life sciences leaders to enhance scientific and business understanding, augment deal flow and connections
- Innovate: Dive deep on the most relevant science and business topics driving industry’s innovation challenges
1) Anika pops after the FDA finally approves its arthritis jab - Fierce Biotech, February 26, 2014
After two stinging rejections sent it back to the lab, Anika Therapeutics has secured the FDA’s blessing for an osteoarthritis pain injection, propelling the biotech’s shares up more than 40%. Link
2) FDA approves Bristol-Myers drug for rare body fat disorder - Reuters, February 25, 2014
Bristol-Myers Squibb Co said the U.S. Food and Drug Administration approved its drug to treat rare and potentially fatal disorders involving loss of body fat. The drugmaker had co-developed the drug with AstraZeneca. Link
3) Revamped Radius Health Looks to Cash In With $86M IPO - Xconomy, February 27, 2014
Radius Health has raised more than $250 million from private investors to develop an osteoporosis drug to pit against Eli Lilly’s teriparatide (Forteo). Link
4) Vertex eyes another $45 million in sales as FDA swells Kalydeco’s patient pool - Fierce Pharma, February 24, 2014
Any drugmaker knows that no matter what a drug’s sticker price, its sales can only go as far as its patient pool will take it. So for Vertex, whose cystic fibrosis med Kalydeco had reached nearly all eligible patients in the U.S. and Europe, a new FDA approval to treat more CF sufferers is pretty significant. Link
5) Bristol-Myers picks up another ‘breakthrough’ trophy in hep C cocktail showdown - Fierce Biotech, February 24, 2014
Bristol-Myers Squibb has picked up its second “breakthrough” drug designation for a daclatasvir-based, all-oral combo for hepatitis C from the FDA, potentially shaving some regulatory time off its late-stage program as developers scramble to hijack market share from Gilead’s pioneering approach. Link